OFI Invest Asset Management Buys Shares of 910 Zimmer Biomet Holdings, Inc. $ZBH

OFI Invest Asset Management bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 910 shares of the medical equipment provider’s stock, valued at approximately $83,000.

Other large investors have also recently bought and sold shares of the company. Garde Capital Inc. acquired a new stake in Zimmer Biomet during the 1st quarter valued at $29,000. Washington Trust Advisors Inc. acquired a new stake in Zimmer Biomet during the 1st quarter valued at $30,000. Columbia River Financial Group LLC acquired a new stake in Zimmer Biomet during the 1st quarter valued at $30,000. Accent Capital Management LLC acquired a new stake in Zimmer Biomet during the 1st quarter valued at $35,000. Finally, Cullen Frost Bankers Inc. grew its holdings in Zimmer Biomet by 1,452.4% during the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 305 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 0.4%

Shares of ZBH opened at $95.13 on Tuesday. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $18.85 billion, a P/E ratio of 23.15, a price-to-earnings-growth ratio of 2.18 and a beta of 0.67. The stock’s fifty day simple moving average is $101.36 and its 200 day simple moving average is $98.03. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $114.72.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same period last year, the company posted $2.01 EPS. The business’s quarterly revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several analyst reports. BTIG Research raised their price objective on Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. Rothschild Redb upgraded Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Evercore ISI decreased their price objective on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a report on Tuesday, October 7th. Finally, UBS Group raised their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $113.16.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.